Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146810 | 0.86 | LMNA (0.43) | LMNAHPGDPTPN1ALDH1A1USP2 | |
| SCHEMBL2147308 | 0.77 | CCNB2 (0.47) | LMNAHPGDPTPN1ALDH1A1USP2 | |
| SCHEMBL1503247 | 0.77 | AR (0.45) | LMNAHPGDALDH1A1NPC1RAB9A | |
| SCHEMBL2146961 | 0.75 | LMNA (0.39) | LMNAALDH1A1FFAR1MAPTNPC1 | |
| SCHEMBL2146762 | 0.72 | LMNA (0.50) | LMNAHPGDPTPN1ALDH1A1USP2 | |
| SCHEMBL1503281 | 0.72 | LMNA (0.50) | LMNAHPGDPTPN1ALDH1A1USP2 | |
| SCHEMBL2146827 | 0.71 | HSD11B1 (0.34) | LMNAALDH1A1SLC6A3MAPTKDM4E | |
| SCHEMBL13850950 | 0.71 | LMNA (0.44) | LMNAHPGDALDH1A1USP2TSHR | |
| SCHEMBL2187912 | 0.69 | MAPT (0.58) | LMNAHPGDALDH1A1MAPTRAB9A | |
| SCHEMBL83038 | 0.69 | LMNA (0.58) | LMNAHPGDALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664248-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | TAIMED BIOLOGICS, INC. (TW) | 2014-03-04 | — | — | US | disclosed |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA, INC. (CA) | 2012-12-27 | — | — | US | disclosed |
| EP-2526091-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TaiMed Biologics, Inc. (TW) | 2012-11-28 | — | — | EP | disclosed |
| US-8283366-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | AMBRILIA BIOPHARMA, INC. (CA) | 2012-10-09 | — | — | US | disclosed |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TAIMED BIOLOGICS, INC. (TW) | 2011-07-28 | — | — | US | disclosed |
| WO-2011088549-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA INC. (CA) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | LMNA 1522/4885HPGD 83/4885PTPN1 2384/4885 |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | LMNA 1522/4885HPGD 83/4885PTPN1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.